Granzyme B (GZMB)-Positive Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma: Significance as a Prognostic Factor and Association with Immunosuppressive Proteins.
CD8+ lymphocytes
Granzyme B
Lung adenocarcinoma
Programmed cell death ligand-1
Tumor-infiltrating lymphocytes
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
07
06
2023
accepted:
20
07
2023
pubmed:
17
8
2023
medline:
17
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Granzyme B (GZMB) is a serine protease produced by cytotoxic lymphocytes that reflects the activity of anti-tumor immune responses in tumor-infiltrating lymphocytes (TILs); however, the prognostic significance of GZMB+ TILs in lung adenocarcinoma is poorly understood. We analyzed 273 patients with pathological stage (pStage) I-IIIA lung adenocarcinoma who underwent surgery at Kyushu University from 2003 to 2012. We evaluated GZMB+ TIL counts by immunohistochemistry. We set the cut-off values at 12 cells/0.04 mm GZMB-Low was significantly associated with pStage II-III, PD-L1 positivity, and IDO1 positivity. Disease-free survival (DFS) and overall survival (OS) in the GZMB-Low group were significantly worse than in the GZMB-High group. In multivariable analysis, GZMB-Low was an independent prognostic factor for both DFS and OS. Furthermore, combined prognostic analyses of GZMB+ TILs with PD-L1 or IDO1 showed that GZMB-Low with high expression of these immunosuppressive proteins had the worst prognosis. We analyzed GZMB+ TIL counts in lung adenocarcinoma and elucidated its prognostic significance and association with PD-L1 and IDO1. GZMB+ TIL counts might reflect the patient's immunity against cancer cells and could be a useful prognostic marker of lung adenocarcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Granzyme B (GZMB) is a serine protease produced by cytotoxic lymphocytes that reflects the activity of anti-tumor immune responses in tumor-infiltrating lymphocytes (TILs); however, the prognostic significance of GZMB+ TILs in lung adenocarcinoma is poorly understood.
METHODS
METHODS
We analyzed 273 patients with pathological stage (pStage) I-IIIA lung adenocarcinoma who underwent surgery at Kyushu University from 2003 to 2012. We evaluated GZMB+ TIL counts by immunohistochemistry. We set the cut-off values at 12 cells/0.04 mm
RESULTS
RESULTS
GZMB-Low was significantly associated with pStage II-III, PD-L1 positivity, and IDO1 positivity. Disease-free survival (DFS) and overall survival (OS) in the GZMB-Low group were significantly worse than in the GZMB-High group. In multivariable analysis, GZMB-Low was an independent prognostic factor for both DFS and OS. Furthermore, combined prognostic analyses of GZMB+ TILs with PD-L1 or IDO1 showed that GZMB-Low with high expression of these immunosuppressive proteins had the worst prognosis.
CONCLUSIONS
CONCLUSIONS
We analyzed GZMB+ TIL counts in lung adenocarcinoma and elucidated its prognostic significance and association with PD-L1 and IDO1. GZMB+ TIL counts might reflect the patient's immunity against cancer cells and could be a useful prognostic marker of lung adenocarcinoma.
Identifiants
pubmed: 37587364
doi: 10.1245/s10434-023-14085-z
pii: 10.1245/s10434-023-14085-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7579-7589Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381:2020–31.
doi: 10.1056/NEJMoa1910231
pubmed: 31562796
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537–46.
doi: 10.1200/JCO.18.00149
pubmed: 30620668
Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30.
doi: 10.1016/S0140-6736(18)32409-7
pubmed: 30955977
West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37.
doi: 10.1016/S1470-2045(19)30167-6
pubmed: 31122901
Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342–50.
doi: 10.1056/NEJMoa1809697
pubmed: 30280658
Chen B, Li H, Liu C, et al. Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: a meta-analysis. PLoS One. 2020;15:1–19.
Zeng DQ, Yu YF, Ou QY, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016;7:13765–81.
doi: 10.18632/oncotarget.7282
pubmed: 26871598
pmcid: 4924677
Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem. 2015;37:1560–71.
doi: 10.1159/000438523
pubmed: 26513143
Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94:1003–9.
doi: 10.1111/j.1349-7006.2003.tb01392.x
pubmed: 14611679
Lin C, Chen X, Li M, et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer. 2015;16:e25–35.
doi: 10.1016/j.cllc.2015.02.002
pubmed: 25801750
Kinoshita T, Kudo-Saito C, Muramatsu R, et al. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Eur J Cancer. 2017;86:15–27.
doi: 10.1016/j.ejca.2017.08.026
pubmed: 28950145
Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21:5047–56.
doi: 10.1158/1078-0432.CCR-15-0685
pubmed: 26567364
Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15:388–400.
doi: 10.1038/nri3839
pubmed: 25998963
Akbari B, Farajnia S, Ahdi Khosroshahi S, et al. Immunotoxins in cancer therapy: review and update. Int Rev Immunol. 2017;36:207–19.
doi: 10.1080/08830185.2017.1284211
pubmed: 28282218
Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616–23.
doi: 10.1038/cdd.2009.206
pubmed: 20075940
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Zhai L, Ladomersky E, Lenzen A, et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018;15:447–57.
doi: 10.1038/cmi.2017.143
pubmed: 29375124
pmcid: 6068130
Kim SH, Il Go S, Song DH, et al. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer. 2019;120:547–54.
doi: 10.1038/s41416-019-0398-5
pubmed: 30745585
pmcid: 6461857
Yang H, Shi J, Lin D, et al. Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer. Cancer Med. 2018;7:32–45.
doi: 10.1002/cam4.1243
pubmed: 29168339
Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7–14.
doi: 10.1016/j.ejca.2015.11.020
pubmed: 26771872
Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
doi: 10.1097/JTO.0b013e31812f3c1a
pubmed: 17762336
Kinoshita F, Takada K, Yamada Y, et al. Combined evaluation of tumor-infiltrating CD8 + and FoxP3 + lymphocytes provides accurate prognosis in stage IA lung adenocarcinoma. Ann Surg Oncol. Epub ahead of print 2019. https://doi.org/10.1245/s10434-019-08029-9 .
Takada K, Okamoto T, Shoji F, et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 2016;11:1879–90.
doi: 10.1016/j.jtho.2016.06.006
pubmed: 27346415
Kozuma Y, Takada K, Toyokawa G, et al. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Eur J Cancer. 2018;101:20–9.
doi: 10.1016/j.ejca.2018.06.020
pubmed: 30014971
Wakasu S, Tagawa T, Haratake N, et al. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. Cancer Immunol Immunother. Epub ahead of print January 2023. https://doi.org/10.1007/s00262-022-03353-8 .
Hurkmans DP, Basak EA, Schepers N, et al. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. J Immunother Cancer. 2020;8:1–9.
doi: 10.1136/jitc-2020-000586
Chung JH, Ha JS, Choi J, et al. Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer. Transl Cancer Res. 2022;11:316–26.
doi: 10.21037/tcr-21-2506
pubmed: 35281415
pmcid: 8904957
Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77:2318–27.
doi: 10.1158/0008-5472.CAN-16-3346
pubmed: 28461564
pmcid: 5474226
Nguyen A, Ramesh A, Kumar S, et al. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci Adv. 2020;6:1–17.
doi: 10.1126/sciadv.abc2777
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.
doi: 10.1016/S0140-6736(21)02098-5
pubmed: 34555333
Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386:1973–85.
doi: 10.1056/NEJMoa2202170
pubmed: 35403841
pmcid: 9844511
O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274–86.
doi: 10.1016/S1470-2045(22)00518-6
pubmed: 36108662
Bhat P, Leggatt G, Waterhouse N, et al. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8:e2836.
doi: 10.1038/cddis.2017.67
pubmed: 28569770
pmcid: 5520949
Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta. 2012;413:1338–49.
doi: 10.1016/j.cca.2011.11.006
pubmed: 22120733
Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208–22.
doi: 10.1016/j.jtho.2016.11.2228
pubmed: 27913228